Cabaletta Bio Enters Material Definitive Agreement

TL;DR

Cabaletta Bio just signed a big deal, details TBD.

AI Summary

On September 30, 2024, Cabaletta Bio, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its terms, or any associated financial figures.

Why It Matters

This filing indicates a significant new contract or partnership for Cabaletta Bio, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.

Key Players & Entities

• Cabaletta Bio, Inc. (company) — Registrant
• September 30, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share CABA The Nasdaq Global Se
• $240,000 — rent for the Premises is approximately $240,000 per month, an aggregate of $5.5 million
• $5.5 million — ely $240,000 per month, an aggregate of $5.5 million over the Initial Term under the Lease A

Filing Documents

• caba-20240930.htm (8-K) — 41KB
• 0000950170-24-110389.txt ( ) — 159KB
• caba-20240930.xsd (EX-101.SCH) — 26KB
• caba-20240930_htm.xml (XML) — 5KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement. On September 30, 2024, Cabaletta Bio, Inc. (the " Company ") entered into an Amendment to Service Agreement (the " Lease Amendment ") with CIC Innovation Communities, LLC (" CIC "), to be effective as of October 1, 2024, which amends the Company's existing Service Agreement with CIC, dated as of February 1, 2019, as amended December 1, 2021 (the " Existing Lease " and, together with the Lease Amendment, the " Lease "), to revise the Company's payment obligations and termination rights for office and laboratory space leased under the Existing Lease (the " Premises "). The Lease provides that (i) either party may terminate the Lease or individual office or laboratory space on 30 days', for office space, and 90 days', for laboratory space, written notice by either party for any reason or no reason, and (ii) CIC may terminate the Lease in accordance with certain provisions of the Lease related to breach or bankruptcy. In exchange for discounts to the existing monthly rental fee structure, the Lease Amendment provides that neither party may terminate the lease for the Premises during the period October 1, 2024 through August 31, 2026 (the " Initial Term "), except (i) by mutual agreement, in writing, signed by both parties, or (ii) by CIC in accordance with certain provisions of the Lease related to breach or bankruptcy. The Lease Amendment also provides the Company with an option to extend the Initial Term of the Lease Amendment for two additional 18 month terms (each, an " Extension Term "). Should the Company exercise such option, the termination rights applicable to the Initial Term as set forth in the Lease Amendment will apply to each of the Extension Terms. The aggregate rent for the Premises is approximately $240,000 per month, an aggregate of $5.5 million over the Initial Term under the Lease Amendment. The Registrant plans to file the Lease, encompassing the Existing Lease, as amended, and the Lease

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Cabaletta Bio, Inc. Date: September 30, 2024 By: /s/ Steven Nichtberger Steven Nichtberger, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR